174 related articles for article (PubMed ID: 9658204)
1. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation.
Edgemond WS; Hillard CJ; Falck JR; Kearn CS; Campbell WB
Mol Pharmacol; 1998 Jul; 54(1):180-8. PubMed ID: 9658204
[TBL] [Abstract][Full Text] [Related]
2. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
van der Stelt M; van Kuik JA; Bari M; van Zadelhoff G; Leeflang BR; Veldink GA; Finazzi-Agrò A; Vliegenthart JF; Maccarrone M
J Med Chem; 2002 Aug; 45(17):3709-20. PubMed ID: 12166944
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases.
Veldhuis WB; van der Stelt M; Wadman MW; van Zadelhoff G; Maccarrone M; Fezza F; Veldink GA; Vliegenthart JF; Bär PR; Nicolay K; Di Marzo V
J Neurosci; 2003 May; 23(10):4127-33. PubMed ID: 12764100
[TBL] [Abstract][Full Text] [Related]
4. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A
J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105
[TBL] [Abstract][Full Text] [Related]
5. Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist.
Ueda N; Yamamoto K; Yamamoto S; Tokunaga T; Shirakawa E; Shinkai H; Ogawa M; Sato T; Kudo I; Inoue K
Biochim Biophys Acta; 1995 Jan; 1254(2):127-34. PubMed ID: 7827116
[TBL] [Abstract][Full Text] [Related]
6. Methylation and acetylation of 15-hydroxyanandamide modulate its interaction with the endocannabinoid system.
Amadio D; Fezza F; Catanzaro G; Incani O; van Zadelhoff G; Finazzi Agrò A; Maccarrone M
Biochimie; 2010 Apr; 92(4):378-87. PubMed ID: 20096328
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.
Deutsch DG; Lin S; Hill WA; Morse KL; Salehani D; Arreaza G; Omeir RL; Makriyannis A
Biochem Biophys Res Commun; 1997 Feb; 231(1):217-21. PubMed ID: 9070252
[TBL] [Abstract][Full Text] [Related]
8. Natural and synthetic endocannabinoids and their structure-activity relationships.
Palmer SL; Khanolkar AD; Makriyannis A
Curr Pharm Des; 2000 Sep; 6(13):1381-97. PubMed ID: 10903399
[TBL] [Abstract][Full Text] [Related]
9. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide.
Jonsson KO; Vandevoorde S; Lambert DM; Tiger G; Fowler CJ
Br J Pharmacol; 2001 Aug; 133(8):1263-75. PubMed ID: 11498512
[TBL] [Abstract][Full Text] [Related]
10. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol.
Hillard CJ
Prostaglandins Other Lipid Mediat; 2000 Apr; 61(1-2):3-18. PubMed ID: 10785538
[TBL] [Abstract][Full Text] [Related]
11. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors.
Melck D; Bisogno T; De Petrocellis L; Chuang H; Julius D; Bifulco M; Di Marzo V
Biochem Biophys Res Commun; 1999 Aug; 262(1):275-84. PubMed ID: 10448105
[TBL] [Abstract][Full Text] [Related]
12. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand.
Khanolkar AD; Abadji V; Lin S; Hill WA; Taha G; Abouzid K; Meng Z; Fan P; Makriyannis A
J Med Chem; 1996 Oct; 39(22):4515-9. PubMed ID: 8893848
[TBL] [Abstract][Full Text] [Related]
13. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
Bisogno T; Hanus L; De Petrocellis L; Tchilibon S; Ponde DE; Brandi I; Moriello AS; Davis JB; Mechoulam R; Di Marzo V
Br J Pharmacol; 2001 Oct; 134(4):845-52. PubMed ID: 11606325
[TBL] [Abstract][Full Text] [Related]
14. Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide.
Vandevoorde S; Jonsson KO; Fowler CJ; Lambert DM
J Med Chem; 2003 Apr; 46(8):1440-8. PubMed ID: 12672243
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
16. Novel selective and metabolically stable inhibitors of anandamide cellular uptake.
Ortar G; Ligresti A; De Petrocellis L; Morera E; Di Marzo V
Biochem Pharmacol; 2003 May; 65(9):1473-81. PubMed ID: 12732359
[TBL] [Abstract][Full Text] [Related]
17. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor.
Pratt PF; Hillard CJ; Edgemond WS; Campbell WB
Am J Physiol; 1998 Jan; 274(1):H375-81. PubMed ID: 9458889
[TBL] [Abstract][Full Text] [Related]
18. Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue.
Kempe K; Hsu FF; Bohrer A; Turk J
J Biol Chem; 1996 Jul; 271(29):17287-95. PubMed ID: 8663381
[TBL] [Abstract][Full Text] [Related]
19. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups.
Berglund BA; Boring DL; Wilken GH; Makriyannis A; Howlett AC; Lin S
Prostaglandins Leukot Essent Fatty Acids; 1998 Aug; 59(2):111-8. PubMed ID: 9774174
[TBL] [Abstract][Full Text] [Related]
20. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
